BREAKING🔔 A new study from G2P-Japan🇯🇵 is out at bioRxiv @biorxivpreprint. We elucidated the virological characteristics of SARS-CoV-2 BA.2.86 (aka #Pirola).
*BA.2.86 is has >30 mutations in the genome.
Please RT🔥 1/ biorxiv.org/content/10.110…
Epidemic dynamics modeling by @jampei2 and @JarelElgin showed that the relative effective reproduction number (Re) of BA.2.86 is 1.07-fold higher than that of the currently predominant EG.5.1, suggesting that BA.2.86 has the potential to become the next predominant one. 2/
Growth assay showed that the replication capacity of BA.2.86 is similar to or lower than that of BA.2, its parental strain. BA.2.86 is less replicative than EG.5.1 at the cell culture level. 3/
Four antivirals, molnupiravir (EIDD-1931), nirmatrelvir, remdesivir and ensitrelvir were all effective against BA.2.86. 4/
A cell-based fusion assay showed that the fusogenicity of BA.2.86 spike is a bit (1.5-fold) greater than that of the parental BA.2 spike. 5/
Infection experiments in hamsters showed that both the intrinsic pathogenicity and replication kinetics of BA.2.86 are significantly lower than those of the parental BA.2. 6/
Overall, BA.2.86 does not appear to pose an increased risk to human society. However, it is possible that its virological phenotype may change or even worsen in the future by acquiring additional mutations. Continued monitoring and surveillance are important now and then. 7/7
• • •
Missing some Tweet in this thread? You can try to
force a refresh
BREAKING🔔 The 28th paper from G2P-Japan🇯🇵 is out at Lancet Infectious Diseases @TheLancetInfDis. We elucidated the virological characteristics of new SARS-CoV-2 variant under monitoring, BA.2.86 (aka #Pirola). Please retweet/repost🔥 1/ thelancet.com/journals/lanin…
Here I summarized the mutations detected in BA.2.86. 2/
1⃣Transmissibility/fitness (Re):
Analysis by Jumpei @jampei2 using the data from 🇩🇰 showed that BA.2.86's Re is greater than XBB.1.5 and comparable to or even greater than EG.5.1. 3/
BREAKING🔔 The 27th paper from G2P-Japan🇯🇵 is out at Lancet Infectious Diseases @TheLancetInfDis. We elucidated the virological characteristics of new SARS-CoV-2 variant of interest, EG.5 (aka #Eris) Please RT🔥 1/ thelancet.com/journals/lanin…
Currently, a subvariant of XBB.1.9, EG.5 (aka XBB.1.9.2.5) is well documented in Twitter (maybe aka #X) and elsewhere. 2/
* EG.5.1 S = XBB.1.9.2 S + #Q52H + #F456L
* XBB.1.9.2 S = XBB.1.5 S.
BREAKING🔔 A new study from G2P-Japan🇯🇵 is out! The preprint will be out so soon, but first we show our results on BA.2.86 - transmissibility, infectivity and immune resistance. This would be the 4th non-peer-reviewed🗒, but includes some new stuff. Please retweet/repost🔥 1/
Cf. Non-peer-reviewed works on BA.2.86:
The 1st🗒 from @yunlong_cao :
The 2nd🗒 from @BenjMurrell :
The 3rd🗒 from @BarouchLab :
Here I summarized the mutations detected in BA.2.86. 2/
1⃣Transmissibility/fitness (Re):
Analysis by Jumpei @jampei2 using the data from 🇩🇰 showed that BA.2.86's Re is greater than XBB.1.5 and comparable to or even greater than EG.5.1. 3/
BREAKING🔔 A new preprint from G2P-Japan🇯🇵 is out at bioRxiv @biorxivpreprint. We evaluated the antiviral humoral immunity induced by breakthrough infection (BTI) of XBB subvariants and its effect against a new one, EG.5. Please RT. 1/ biorxiv.org/content/10.110…
Currently, a subvariant of XBB.1.9, EG.5 (aka XBB.1.9.2.5) is well documented in Twitter (maybe aka #X) and elsewhere.
EG.5.1 S = XBB.1.9.2 S + Q52H + F456L, and XBB.1.9.2 S = XBB.1.5 S. 2/
https://t.co/Tm6soayTIV